225 related articles for article (PubMed ID: 27878467)
1. Outcomes of retesting BRCA negative patients using multigene panels.
Yadav S; Reeves A; Campian S; Paine A; Zakalik D
Fam Cancer; 2017 Jul; 16(3):319-328. PubMed ID: 27878467
[TBL] [Abstract][Full Text] [Related]
2. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
3. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
4. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
[TBL] [Abstract][Full Text] [Related]
5. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
6. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
7. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
[TBL] [Abstract][Full Text] [Related]
8. Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
Bernstein-Molho R; Singer A; Laitman Y; Netzer I; Zalmanoviz S; Friedman E
Breast Cancer Res Treat; 2019 Jul; 176(1):165-170. PubMed ID: 30980208
[TBL] [Abstract][Full Text] [Related]
9. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
[TBL] [Abstract][Full Text] [Related]
10. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
12. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
[TBL] [Abstract][Full Text] [Related]
13. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.
Coppa A; Nicolussi A; D'Inzeo S; Capalbo C; Belardinilli F; Colicchia V; Petroni M; Zani M; Ferraro S; Rinaldi C; Buffone A; Bartolazzi A; Screpanti I; Ottini L; Giannini G
Cancer Med; 2018 Jan; 7(1):46-55. PubMed ID: 29271107
[TBL] [Abstract][Full Text] [Related]
15. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
[TBL] [Abstract][Full Text] [Related]
16. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
17. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
18. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
[TBL] [Abstract][Full Text] [Related]
19. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
20. Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing.
Reap L; Ahsan S; Saleh M
Clin Breast Cancer; 2018 Aug; 18(4):e431-e439. PubMed ID: 29739691
[No Abstract] [Full Text] [Related]
[Next] [New Search]